News and publications
13 Jun 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering
3 Nov 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings, 16-19 November 2016
24 Mar 2016: Re-Pharm compound with ‘steroid-sparing properties’ granted second patent for ophthalmic indications
24 Nov 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders
10 Feb 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound
14 May 2014: Company showcase presented at BioTrinity, London.
Publications by, or citing, Re-Pharm.
|David Cavalla||Numedicus Limited||2017|
|Link prescriptions to medical conditions to pave the way for more repurposed drugs||David Cavalla||Numedicus Limited||2016|
|Re-Pharm eyes further advisory pitches for GBP 2.5m Series A raise for ophthalmic drug development||Alexandra Thompson||BioPharm Insight||2016|
|RePharm plans GBP 2.5m Series A in 1Q16 licensing deal by 1H16 – CEO||Reynald Castaneda||BioPharm Insight||2015|
|Smart drug reprofiling||Robert Scoffin||BioPharma Dealmakers||2015|
|Substance Repurposing: Lease of Life||Robert Scoffin, Alan Rothaul||European Biopharmaceutical Review||2015|
In order to develop the drug discovery market and find indications for orphan conditions, alternative methods have to be implemented. Robert Scoffin and Alan Rothaul at Re-Pharm investigate the potential of drug repurposing or re-profiling to address this issue.
|Scoffin, R.; Rothaul, A.||European Biopharmaceutical Review||2013|
Rob Scoffin explores the chemical space around existing drug molecules to provide a lower-risk, lower-cost strategy for the discovery of new chemical entities.
|Scoffin, R.||Innovations in Pharmaceutical Technology||2012|